Recent Study: Czech Republic Pharmaceuticals & Healthcare Report Q2 2015

With recently implemented cost-saving measures, legislative changes, and health insurance reforms, the Czech Republic is set to recover from its recent period of stagnancy and decline. Indeed, these changes will help to provide for the growing demand for innovative drugs among the country's ageing population. The healthcare spending of the Czech population remains superior to that of the less-developed markets of Eastern and South Eastern Europe, demonstrating that demand in these regions will be even higher. In this regard, the task of meeting these demands is one that will weigh heavily on the road to recovery.

Full Report Details at
- http://www.fastmr.com/prod/953214_czech_republic_pharmaceuticals_healthcare_report.aspx?afid=303

Headline Expenditure Projections

* Pharmaceuticals: CZK73.34bn (USD3.30bn) in 2014 to CZK75.31bn (USD3.35bn) in 2014; -3.5% in local currency terms and -7.6% in US dollar terms. Forecasts revised upwards from last quarter.
* Healthcare: CZK303.28bn (USD13.66bn) in 2014 to CZK312.52bn (USD13.90bn) in 2015; +3.0% in local currency terms and 1.8% in US dollar terms. Forecasts revised upwards from last quarter.

Risk/Reward Index: Q215 RRI results for the Czech Republic come in with a Reward score of 62.8 out of 100, a Risk score of 64.1, and an overall score of 63.2 - ranking it as the most attractive market in the Central and Eastern European Region. Drugmakers will face challenges in the Czech pharmaceutical market as a result of pricing pressure, poor access to the market and increasing generic substitution. Additionally, adopted and proposed amendments to healthcare and insurance laws have attracted criticism from the pharmaceutical sector. The Czech pharmaceutical market will nevertheless remain relatively attractive and rewarding due to the regionally high pharmaceutical expenditure per capita compared with its neighbours, an ageing population and a favourable urban-rural distribution.

Key Trends And Developments

Czech Republic President Milos Zeman has signed a government amendment to law on public health insurance. The new law, which was...

The Czech Republic Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Czech Republic Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Czech Republic pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Czech Republic, to test other views - a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Mexico Pharmaceuticals & Healthcare Report Q2 2015
- Thailand Pharmaceuticals & Healthcare Report Q2 2015
- Croatia Pharmaceuticals & Healthcare Report Q2 2015
- Kenya Pharmaceuticals & Healthcare Report Q2 2015